The selective response of a fraction of NSCLC to these agents can be explained by somatic mutations in the tyrosine kinase domain of EGFR in most patients with NSCLC responsive to gefitinib or erlotinib [23-25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.